PDS Biotechnology Corporation
$1.29
▲
4.73%
2026-04-21 08:47:01
www.pdsbiotech.com
NCM: PDSB
Explore PDS Biotechnology Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$72 M
Current Price
$1.29
52W High / Low
$1.92 / $0.51
Stock P/E
—
Book Value
$-4.02
Dividend Yield
—
ROCE
-150.13%
ROE
-2.44%
Face Value
—
EPS
$-0.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.19
Debt / Equity
182.94
Current Ratio
2.98
Quick Ratio
2.98
Forward P/E
-2.01
Price / Sales
—
Enterprise Value
$50.49 M
EV / EBITDA
-1.6
EV / Revenue
—
Rating
Strong Buy
Target Price
$7.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 2. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 3. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 4. | Eikon Therapeutics, Inc. | $11.55 | — | $644.25 M | — | -62.8% | -1.25% | $17.4 / $8.58 | $-286.47 |
| 5. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 6. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 7. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.67 M | -8.14 M | -7.62 M | -9.11 M | -7.36 M | — |
| Net Profit | -7.56 M | -9.01 M | -9.43 M | -8.49 M | -7.95 M | — |
| EPS in Rs | -0.14 | -0.16 | -0.17 | -0.15 | -0.14 | -0.29 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -31.54 M | -36.32 M | -43.05 M | -41.67 M |
| Net Profit | -34.5 M | -37.61 M | -42.94 M | -40.85 M |
| EPS in Rs | -0.62 | -0.67 | -0.77 | -0.73 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 30.49 M | 45.36 M | 59.39 M | 77.01 M |
| Total Liabilities | 21.24 M | 26.35 M | 33.26 M | 33.01 M |
| Equity | 9.25 M | 19 M | 26.13 M | 44 M |
| Current Assets | 28.25 M | 45.05 M | 59.06 M | 76.48 M |
| Current Liabilities | 9.48 M | 17.09 M | 13.63 M | 9.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27.75 M | -35.03 M | -33.64 M | -25.71 M |
| Investing CF | 0 M | -0.03 M | 0 M | — |
| Financing CF | 12.77 M | 20.19 M | 16.38 M | 34.29 M |
| Free CF | -27.75 M | -35.06 M | -33.64 M | -25.71 M |
| Capex | — | -0.03 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 8.28% | 12.42% | -5.11% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.